• About Us
    • Our Company
    • Our People
  • Our Science
    • Our Science
    • Precise Antibody Engineering
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
  • Pipeline
    • Pipeline
    • MMB101
    • MMB102
    • MFA011
  • Partnering
  • News
  • About Us
    • Our Company
    • Our People
  • Our Science
    • Our Science
    • Precise Antibody Engineering
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
  • Pipeline
    • Pipeline
    • MMB101
    • MMB102
    • MFA011
  • Partnering
  • News

  • About us
    • Our Company
    • Our People
  • Contact
  • Home
  • Our Science
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
    • Precise Antibody Engineering
  • Partnering with Us
  • Pipeline
    • MFA011
    • MMB101
    • MMB102

Pipeline

  • Pipeline
  • MMB101
  • MMB102
  • MFA011

한글 MMB101

anti-TIGIT mAb

MMB101 is a humanized anti-TIGIT monoclonal antibody designed to target a novel epitope spanning multiple PVR binding sites for optimized functional coverage.

  • Differentiated epitope coverage to benchmark anti-TIGIT antibodies
  • Preclinical evidence of anti-tumor activity in multiple cancer models
  • Functional synergism with PD-1 drugs
  • Immunomodulation of central memory T cells (Tcm) and effector memory T cells (Tem) for long-term response

  • Home
  • Our Company
    • Our Company
    • Our People
  • Our Science
    • Our Science
    • Precise Antibody Engineering
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
  • Pipeline
    • Pipeline
    • MMB101
    • MMB102
    • MFA011
  • Partnering with Us
  • News
  • Contact

#721, 54, Changeop-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13449 Tel. 82-(0)31-623-2100 Fax. 82-(0)31-751-2101 Email. info@medimabbio.com

©MEDIMABBIO. ALL RIGHTS RESERVED.